Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly price for cash-paying U.S. patients with Type 2 diabetes from its previous list price of nearly $1,000 to just $499. The news follows mounting calls for greater drug affordability and may signal a pivotal shift in the pharmaceutical pricing landscape.
Details of the price cut
- Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover Ozempic. More than 70,000 U.S. pharmacies are participating through partnerships with GoodRx and NovoCare, Novo Nordisk’s cash-pay pharmacy.
- What’s the new price? $499 per month for Ozempic (all strengths), compared with the prior list price of $997. Wegovy, another semaglutide-based drug from Novo, is also available at this price point for cash buyers.
- How to access the offer: Eligible patients can obtain Ozempic at the discounted price by paying out of pocket at participating pharmacies or ordering online with home delivery via NovoCare or GoodRx.
Rationale behind the move
Novo Nordisk said the decision is part of an ongoing effort to make authentic, FDA-approved semaglutide medicines more accessible, especially to those who might otherwise turn to unsafe, compounded alternatives. The company emphasized that affordability is not only a response to competitive market pressures—including Eli Lilly’s continued expansion in diabetes and obesity treatments—but also a direct effort to prioritize patient safety and access.
“Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk,” said Dave Moore, executive vice president, U.S. operations, at Novo Nordisk. “While Ozempic is well covered in the U.S., let’s not forget that there are some patients who pay out-of-pocket for this vital medicine. We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that’s one too many.”
Following the announcement, shares of Novo Nordisk jumped nearly 5%, while GoodRx surged close to 40%. Analysts see the price cut as a proactive response to rival drug launches and ongoing political scrutiny over high U.S. drug prices.
To be clear, most insured diabetes patients in the U.S. already pay far less than the full list price for Ozempic; usually, it comes out to just under $25 per month. However, the new program is targeted specifically at uninsured or underinsured people who face the steepest out-of-pocket costs. The price reduction also comes shortly after Wegovy received FDA approval for use as a liver-disease treatment, broadening its indications and market reach.
For this story, Fortune used generative AI to help with an initial draft. An editor verified the accuracy of the information before publishing.
